Company / Operating Cash Flow
Spero Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$23.4M
FY2025
5-year range
-$85.9M / -$7.7M
FY2021-FY2025
Trend
+28.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 8 years, ranging from -$86M in FY2021 to -$8M in FY2023.
Based on SEC 10-K filings.
-$23M in FY2025.
Declined from -$8M to -$23M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 28.9% year-over-year.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$23.4M | +28.9% |
| FY2024 | -$33.0M | -326.8% |
| FY2023 | -$7.7M | +88.0% |
| FY2022 | -$64.3M | +25.1% |
| FY2021 | -$85.9M | -71.7% |
| FY2020 | -$50.0M | -26.2% |
| FY2019 | -$39.6M | -36.8% |
| FY2018 | -$29.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026